Helicobacter Pylori Infection
Conditions
Keywords
Helicobacter pylori Therapy
Brief summary
Rifabutin has good chemical stability and low drug resistance rate in acidic gastric environment. Therefore, it is often used in combination with amoxicillin proton pump inhibitor for the rescue treatment of Helicobacter pylori. The purpose of this study was to evaluate the efficacy and safety of rifabutin-containing triple therapy versus classical bismuth-containing quadruple therapy as rescue therapy for the eradication of refractory Helicobacter pylori
Interventions
DRUGEsomeprazole
Proton pump inhibitor
DRUGBismuth Potassium Citrate
Gastric mucosal protective drug with anti-H. pylori effect
Antibiotics for H. pylori eradication
DRUGamoxicillin rifabutin
Antibiotics for H. pylori eradication
Sponsors
Shanghai Jiao Tong University School of Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* ability and willingness to participate in the study and to sign and give informed consent * Confirmed H. pylori infection and with previous treatment experience
Exclusion criteria
* Less than 18 years old * With previous gastric surgery * Previous history of tuberculosis * Major systemic diseases * Pregnancy or lactation * Allergy to any of the study drugs Administration of antibiotics, bismuth, antisecretory drugs in 8 weeks prior to inclusion
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Helicobacter pylori eradication rate | Six weeks after completion of therapy | Six weeks after completion of therapy, H. pylori eradication was assessed by ¹³C-urea breath test. Eradication was |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Compliance rate | Within 7 days after completion of therapy | Compliance was defined as poor when they had taken less than 80% of the total medication |
Countries
China
Outcome results
None listed